卵巢癌

Cancer Research UK. Ovarian cancer: cancer statistics - key facts. June 2014. http://info.cancerresearchuk.org (last accessed 26 January 2017).

• 全文

American Cancer Society. Cancer facts and figures, 2017. http://www.cancer.org (last accessed 26 January 2017).

• 全文

Cannistra S. Medical progress: cancer of the ovary. N Engl J Med. 2004;351:2519-2529.

• 摘要

Frank TS. Testing for hereditary risk of ovarian cancer. Cancer Control. 1999;6:327-334.

• 摘要

Goff BA, Mandel L, Muntz HG, et al. Ovarian cancer diagnosis: results of a national ovarian cancer survey. Cancer. 2000;89:2068-2075.

• 摘要

Goff BA, Mandel LS, Melancon CH, et al. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 2004;291:2705-2712.

• 摘要

Benedet JL, Bender H, Jones H 3rd, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynaecol Obstet. 2000;70:209-262.

• 摘要

Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New Engl J Med. 2006;354:34-43.

• 摘要

Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374:1331-1338.

• 摘要

1.  Fleming GF, Ronette BM, Seidman J, et al. Epithelial ovarian cancer. In: Barakat RR, Markman M, Randall ME, eds. Principles and practice of gynecologic oncology. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2009.

2.  World Health Organization. Classification of tumours, pathology, and genetics of tumours of the breast and female genital organs. Lyon, IARC Press; 2003.

3.  Cancer Research UK. Ovarian cancer: cancer statistics - key facts. June 2014. http://info.cancerresearchuk.org (last accessed 26 January 2017).

• 全文

4.  American Cancer Society. Cancer facts and figures, 2017. http://www.cancer.org (last accessed 26 January 2017).

• 全文

5.  American Cancer Society. Global cancer facts and figures: 3rd edition. 2012. http://www.cancer.org (last accessed 26 January 2017).

• 全文

6.  Cannistra S. Medical progress: cancer of the ovary. N Engl J Med. 2004;351:2519-2529.

• 摘要

7.  Frank TS. Testing for hereditary risk of ovarian cancer. Cancer Control. 1999;6:327-334.

• 摘要

8.  Bewtra C, Watson P, Conway T, et al. Hereditary ovarian cancer: a clinicopathological study. Int J Gynecol Pathol. 1992;11:180-187.

• 摘要

9.  Crum CP, Drapkin R, Kindelberger D, et al. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res. 2007;5:35-44.

• 全文
• 摘要

10.  Singer G, Stohr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis. A mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005;29:218-224.

• 摘要

11.  Hartmann LC, Podratz KC, Keeney GL, et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol. 1994;12:64-69.

• 摘要

12.  Rose PG, Piver MS, Tsukada Y, et al. Metastatic patterns in histologic variants of ovarian cancer: an autopsy study. Cancer. 1989;64:1508-1513.

• 摘要

13.  Knudson AG. Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol. 1996;122:135-140.

• 摘要

14.  American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol. 2009;113:957-966.

• 摘要

15.  Kerlikowske K, Brown JS, Grady DG. Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol. 1992;80:700-707.

• 摘要

16.  Ness RB, Grisso JA, Klapper J, et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions. Am J Epidemiol. 2000;152:233-241.

• 摘要

17.  Whittemore AS, Wu ML, Paffenbarger RS Jr, et al. Personal and environmental characteristics related to epithelial ovarian cancer. II. Exposures to talcum powder, tobacco, alcohol, and coffee. Am J Epidemiol. 1988;128:1228-1240.

• 摘要

18.  DiSaia P. Clinical gynecologic oncology. 6th ed. London, UK: Harcourt International; 2002.

19.  Leitzmann MF, Koebnick C, Danforth KN, et al. Body mass index and risk of ovarian cancer. Cancer. 2009;115:812-822.

• 摘要

20.  Collaborative Group On Epidemiological Studies Of Ovarian Cancer; Beral V, Gaitskell K, Hermon C, et al. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet. 2015;385:1835-1842.

• 全文
• 摘要

21.  Crane K. Oral contraceptives as ovarian cancer prevention. J Natl Cancer Inst. 2011;103:1286-1288.

• 摘要

22.  Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101:80-87.

• 摘要

23.  Society of Gynecologic Oncology. SGO clinical practice statement: salpingectomy for ovarian cancer prevention. November 2013. http://www.sgo.org/ (last accessed 14 February 2017).

• 全文

24.  Goff BA, Mandel L, Muntz HG, et al. Ovarian cancer diagnosis: results of a national ovarian cancer survey. Cancer. 2000;89:2068-2075.

• 摘要

25.  Goff BA, Mandel LS, Melancon CH, et al. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 2004;291:2705-2712.

• 摘要

26.  Dodge JE, Covens AL, Lacchetti C, et al. Management of a suspicious adnexal mass: a clinical practice guideline. Curr Oncol. 2012;19:e244-e257.

• 全文
• 摘要

27.  Spencer JA. A multidisciplinary approach to ovarian cancer at diagnosis. Br J Radiol. 2005;78:s94-s102.

• 摘要

28.  Kitajima K, Suzuki K, Senda M, et al. FDG-PET/CT for diagnosis of primary ovarian cancer. Nucl Med Commun. 2011;32:549-553.

• 摘要

29.  Le T, Giede C, Salem S, et al. Initial evaluation and referral guidelines for management of pelvic/ovarian masses. J Obstet Gynaecol Can. 2009;31:668-680.

• 全文
• 摘要

30.  Einhorn N, Sjovall K, Knapp RC, et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol. 1992;80:14-18.

• 摘要

31.  Rustin GJ, van der Burg ME, Griffin CL, et al; MRC OV05; EORTC 55955 investigators. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376:1155-1163.

• 摘要

32.  Society of Gynecologic Oncologists. Statement regarding OvaSure™. July 2008. http://www.sgo.org (last accessed 26 January 2017).

• 全文

33.  Ueland FR, Desimone CP, Seamon LG, et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol. 2011;117:1289-1297.

• 摘要

34.  Benedet JL, Bender H, Jones H 3rd, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynaecol Obstet. 2000;70:209-262.

• 摘要

35.  Karlan BY, Platt LD. The current status of ultrasound and color Doppler imaging in screening for ovarian cancer. Gynecol Oncol. 1994;55:S28-S33.

• 摘要

36.  Lavin PT, Knapp RC, Malkasian G, et al. CA-125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol. 1987;69:223-227.

• 摘要

37.  American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Committee Opinion No. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol. 2011;117:742-746.

• 摘要

38.  Vergote IB, Bormer OP, Abeler VM. Evaluation of serum CA 125 levels in the monitorin of ovarian cancer. Am J Obstet Gynecol. 1987;157:88-92.

• 摘要

39.  Antila R, Jalkanen J, Heikinheimo O. Comparison of secondary and primary ovarian malignancies reveals differences in their pre- and peri-operative characteristics. Gynecol Oncol. 2006;101:97-101.

• 摘要

40.  Floch CL. Diagnosis and management of acute diverticulitis. J Clin Gastroenterol. 2006;40:s136-s144.

• 摘要

41.  Qaseem A, Humphrey LL, Harris R, et al. Screening pelvic examination in adult women: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2014;161:67-72.

• 全文
• 摘要

42.  Jacobs I, Davies AP, Bridges J, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA125 measurement and ultrasonography. BMJ. 1993;306:1030-1034.

• 摘要

43.  Partridge E, Kreimer AR, Greenlee RT, et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol. 2009;113:775-782.

• 摘要

44.  Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305:2295-2303.

• 全文
• 摘要

45.  Skates SJ. Ovarian cancer screening: development of the risk of ovarian cancer algorithm (ROCA) and ROCA screening trials. Int J Gynecol Cancer. 2012;22(suppl 1):S24-S26.

• 全文
• 摘要

46.  Lu KH, Skates S, Hernandez MA, et al. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer. 2013;119:3454-3461.

• 摘要

47.  Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009;10:327-340.

• 摘要

48.  Moyer VA; U.S. Preventive Services Task Force. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2012;157:900-904.

• 全文
• 摘要

49.  Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA-1 or BRCA-2 mutation. New Engl J Med. 2002;346:1609-1615.

• 全文
• 摘要

50.  American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 89. Elective and risk-reducing salpingo-oophorectomy. Obstet Gynecol. 2008;111:231-241.

• 摘要

51.  Moorman PG, Havrilesky LJ, Gierisch JM, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol. 2013;31:4188-4198.

• 摘要

52.  Vergote I, Trope CG, Amant F, et al; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943-953.

• 全文
• 摘要

53.  Young RC, Decker DG, Wharton JT, et al. Staging laparotomy in early ovarian cancer. JAMA. 1983;250:3072-3076.

• 摘要

54.  Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248-1259.

• 摘要

55.  Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. New Engl J Med. 1990;322:1021-1027.

• 摘要

56.  Winter-Roach BA, Kitchener HC, Dickinson HO. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev. 2009;(3):CD004706.

• 摘要

57.  Bell J, Brady MF, Young RC, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2006;102:432-439.

• 摘要

58.  Vasey PA, Atkinson R, Osborne R, et al. SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer. Br J Cancer. 2006;94:62-68.

• 摘要

59.  Bristow RE, Eisenhauer EL, Santillan A, et al. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol. 2007;104:480-490.

• 摘要

60.  Tangjitgamol S, Manusirivithaya S, Laopaiboon M, et al. Interval debulking surgery for advanced epithelial ovarian cancer: a Cochrane systematic review. Gynecol Oncol. 2009;112:257-264.

• 摘要

61.  Gerestein CG, Damhuis RA, Burger CW, et al. Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review. Gynecol Oncol. 2009;114:523-527.

• 摘要

62.  Fung-Kee-Fung M, Provencher D, Rosen B, et al. Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care. Gynecol Oncol. 2007;105:747-756.

• 摘要

63.  Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New Engl J Med. 2006;354:34-43.

• 摘要

64.  Markman M, Bundy BM, Alberts DS, et al. Phase III trial of standard dose intravenous carboplatin plus paclitaxel versus moderately high dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001-1007.

• 摘要

65.  Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. New Engl J Med. 1996;335:1950-1955.

• 摘要

66.  Wenzel LB, Huang HQ, Armstrong DK, et al. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2007;25:437-443.

• 摘要

67.  National Horizon Scanning Centre (NHSC). Trabectedin (Yondelis) for ovarian cancer - relapsed, second line: horizon scanning technology briefing (project). 2009.

68.  Fujiwara K, Armstrong D, Morgan M, et al. Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer. 2007;17:1-20.

• 摘要

69.  Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27:1419-1425.

• 摘要

70.  Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003;21:2460-2465.

• 摘要

71.  Burger RA, Brady MF, Bookman MA, et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study. J Clin Oncol. 2010;(suppl):LBA1.

• 全文

72.  ICON 7. Bevacizumab in ovarian cancer. http://www.icon7trial.org (last accessed 26 January 2017).

• 全文

73.  Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374:1331-1338.

• 摘要

74.  Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 2013;14:1020-1026.

• 摘要

75.  Pujade-Lauraine E, Wagner U, Avall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010;28:3323-3329.

• 摘要

76.  Wagner U, Marth C, Largillier R, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 2012;107:588-591.

• 全文
• 摘要

77.  Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24:4699-4707.

• 全文
• 摘要

78.  Hanker LC, Loibl S, Burchardi N, et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 2012;23:2605-2612.

• 摘要

79.  Williams CJ. Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev. 2001;(1):CD001034.

• 摘要

80.  Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32:1302-1308.

• 全文
• 摘要

81.  Underhill C, Toulmonde M, Bonnefoi H. A review of PARP inhibitors: from bench to bedside. Ann Oncol. 2011;22:268-279.

• 摘要

82.  Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382-1392.

• 全文
• 摘要

83.  Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33:244-250.

• 全文
• 摘要

84.  Oza AM, Cibula D, Benzaquen AO, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2015;16:87-97.

• 摘要

85.  Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010;28:3107-3114.

• 摘要

86.  National Institute for Health and Care Excellence. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer. April 2016. http://www.nice.org.uk (last accessed 26 January 2017).

• 全文

87.  Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur J Cancer. 2012;48:2361-2368.

• 摘要

88.  Krasner CN, Poveda A, Herzog TJ, et al. Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone. Gynecol Oncol. 2012;127:161-167.

• 摘要

89.  Ledermann JA, Perren T, Raja FA, et al. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial. http://conference.ncri.org.uk (last accessed 26 January 2017).

• 全文

90.  Monk BJ, Poveda A, Vergote I, et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15:799-808.

• 摘要

91.  du Bois A, Floquet A, Kim JW, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014;32:3374-82.

• 摘要

92.  Maxwell GL, Synan I, Dodge R, et al. Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial. Obstet Gynecol. 2001;98:989-995.

• 摘要

93.  Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second-line therapy for platinum resistant and platinum sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 1998;16:405-410.

• 摘要

94.  Holschneider CH, Berek JS. Cytoreductive surgery: principles and rationale. In: Bristow RE, Karlan BY, eds. Surgery for ovarian cancer: principles and practice. London, UK: Taylor and Francis; 2006:99-101.

95.  Itani KM, Wilson SE, Awad SS, et al. Ertapenem versus cefotetan prophylaxis in elective colorectal surgery. N Engl J Med. 2006;355:2640-2651.

• 摘要

96.  Madjdpour C, Spahn DR, Weiskopf RB. Anemia and perioperative red blood cell transfusion: a matter of tolerance. Crit Care Med. 2006;35:S102-S108.

• 摘要

97.  De Oliveira GS Jr, Schink JC, Buoy C, et al. The association between allogeneic perioperative blood transfusion on tumour recurrence and survival in patients with advanced ovarian cancer. Transfus Med. 2012;22:97-103.

• 摘要

98.  Cheatham ML, Chapman WC, Key SP, et al. A meta-analysis of selective versus routine nasogastric decompression after elective laparotomy. Ann Surg. 1995;221:476-478.

• 摘要

99.  Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data. Medicine. 1999;78:285-291.

• 摘要

100.  Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2004;140:175-183.

• 摘要

101.  Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346:975-980.

• 摘要

102.  Schwartz PE, Rutherford TJ, Chambers JT, et al. Neoadjuvant chemotherapy for advanced ovarian cancer: long term survival. Gynecol Oncol. 1999;72:93-99.

• 摘要

103.  Rubin SC, Hoskins WJ, Benjamin I, et al. Palliative surgery for intestinal obstruction in advanced ovarian cancer. Gynecol Oncol. 1989;34:16-19.

• 摘要

104.  Numnum TM, Rocconi RP, Whitworth J, et al. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian cancer. Gynecol Oncol. 2006;102:425-428.

• 摘要

105.  Markman M, Hall J, Spitz D, et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol. 2002;20:2365-2369.

• 摘要

106.  Torramade JR, Cienfuegos JA, Hernandez, et al. The complications of central venous access systems: a study of 218 patients. Eur J Surg. 1993;159:323-327.

• 摘要

107.  Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;100:27-32.

• 摘要

108.  Risum S, Langer SW. Plantar-palmar erythrodysesthesia. A new and relatively frequent side effect in antineoplastic treatment. Ugeskr Laeger 2003;165:3161-3162. [in Danish]

• 摘要

109.  Lopez AM, Wallace L, Dorr RT, et al. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol. 1999;44:303-306.

• 摘要

110.  Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol. 2000;1:225-234.

• 摘要

111.  Cannistra SA, Matulonis U, Penson R, et al. Bevacizumab in patients with advanced platinum resistant ovarian cancer. J Clin Oncol. 2006;24(suppl 18):5006.

• 全文

112.  Cancer Australia. Follow up of women with epithelial ovarian cancer. September 2012. http://guidelines.canceraustralia.gov.au (last accessed 26 January 2017).

• 全文

113.  Society of Gynecologic Oncologists. Use of CA125 for monitoring ovarian cancer. June 2009. http://www.sgo.org (last accessed 26 January 2017).

• 全文

114.  Ozols RF, Bundy BM, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194-3200.

• 摘要